Navigation Links
Drug in new class of targeted therapies shows early promise against blood-related cancers
Date:5/19/2010

HACKENSACK, N.J. (May 19, 2010) A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia (CLL). Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers. The drug did not demonstrate any clinical effect against advanced multiple myeloma, although researchers hope it might still prove to have some benefit against this blood cancer as part of combination therapy. The paper is published online in the Journal of Clinical Oncology.

"No drugs that target this cancer mechanism are on the market today," says study author David S. Siegel, M.D., Ph.D., Co-Chief, Multiple Myeloma, John Theurer Cancer Center at Hackensack University Medical Center. "I am hopeful that larger studies will show that this targeted therapy is useful against a number of advanced B cell malignancies."

Chronic lymphocytic leukemia (CLL) and multiple myeloma are both considered B cell malignancies, as they attack these cells, also known as B lymphocytes. B lymphocytes are white blood cells that develop in the bone marrow and make antibodies that protect the immune system. Both types of blood cancer leave their victims susceptible to infections and other serious complications. While there are treatments for both cancers, there is no cure, and more effective treatments are needed.

"At the John Theurer Cancer Center we are committed to exploring new treatment options for rare cancers, such as multiple myeloma and CLL," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chairman and Executive Administrative Director, John Theurer Cancer Center. "We will continue to research new therapies to help our patients live longer and to find a cure for these diseases."

Dr. Siegel and colleagues tested the new medication on 37 patients, 19 with CLL and 18 with myeloma. Patients recruited to the study had advanced disease that was in relapse, and all had been through previous treatments with other medications (median number of prior treatments: four). All patients were given SNS-032, and all were aware of what they were taking.

To test both the drug's safety and the best potential dose, SNS-032 was given intravenously as a "loading" dose an initially higher dose that is then reduced to a maintenance level over five minutes. This was followed by a six-hour infusion given to all patients on a weekly basis for three consecutive weeks.

Although the primary purpose of the study was to test the maximum safe dose that could be given to patients, Dr. Siegel and colleagues also looked at whether the medication had an effect on disease processes. One patient with CLL had more than a 50 percent reduction in measurable disease, but no improvement in disease markers in the blood. Another CLL patient had stable disease for four courses of treatment. For multiple myeloma, two patients had stable disease with treatment and one had normalization of spleen size, which is an indication of a reduction in blood cancer activity.

Looking at blood test results for the patients, the researchers found anti-cancer activity. The drug appeared to inhibit cyclindependent kinases 7 and 9, two of the three enzymatic proteins targeted in this study. They also caused apoptosis, or cell death, in cancer cells.

"Our study found that this drug is well tolerated and had some clinical effect, but it is important to note that this was a small, very early stage study," says Dr. Siegel. "Based on these findings, there is justification for additional research, which will show whether this drug has a place in the arsenal of treatments for hematologic malignancies."

Preclinical studies of SNS-032 demonstrated that the drug inhibited the growth of cancer cells, and induced apoptosis, in B cell malignancies.

"The results of the preclinical studies suggest that we might see more anti-tumor effects if the drug is given over a longer period, possibly eight hours or more," adds Dr. Siegel. "Because the patients in the study were at a late disease stage and heavily pretreated, we might also see more of a response in earlier-stage patients. Future studies could look at these issues, as well as the feasibility of using SNS-032 in combination with other therapies."


'/>"/>

Contact: Amy Leahing
amy.leahing@widmeyer.com
646-213-7245
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. Retirement Community in Arizona Hosts Classic Car Show with Live Music
2. ‘Best in Class' Nursing Homes Recognized for Exemplary Customer, Workforce Satisfaction
3. Martin & Jones Announces Class Action Lawsuit Against Major Employer, Claims Thousands of Visiting Nurses Illegally Denied Overtime Pay
4. A medicine classic goes online and far afield
5. MetaGeek Announces Chanalyzer Pro Spectrum Analysis Software for Wi- Spy, Adds Device Classification, Device Finder and Automated Reports
6. Classic Maya history is embedded in commoners homes
7. New class of drug kills lymphoma cells
8. Exposure to 3 classes of common chemicals may affect female development
9. HealthLinkRx Announces Classes in Spanish for Occupational and Physical Therapists
10. Dr. Khanna to Attend the 13th annual Women in Film Malibu Golf Classic
11. Bad Habits Explain Class Differences in Health: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... 04, 2016 , ... "Pro3rd Displace is a set of ... displacement design elements," said Christina Austin - CEO of Pixel Film Studios. ... of design styles that include both left aligned and right aligned options for ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global ... Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New York ... who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the ...
(Date:12/2/2016)... ... 02, 2016 , ... Advanced Inc., a leading provider of travel therapy and ... to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously ... financial and operational leadership experience to Advanced Inc. He began his career in finance ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs ... patients must find the one that works for them. When an inventor from Suisun ... that worked and decided to share it with others. , He developed a prototype ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... N.J. , Dec. 3, 2016  Findings ... and safety of CTL019, an investigational chimeric antigen ... (r/r) pediatric and young adult patients with B-cell ... during an oral session at the 58th American ... December 3, 4:00-5:30 p.m.). The global Phase II ...
(Date:12/2/2016)... bioLytical Laboratories, un líder mundial en test rápidos de ... Self Test , a los miembros de la Kenya Pharmaceutical Association. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la Clinton ...
(Date:12/2/2016)... According to the latest market report ... Automated Endoscope Reprocessors: Single Basin Automated Endoscope Reprocessors Product Type ... and 2024 " the global automated endoscope reprocessors market was valued at US$ ... a CAGR of 7.2% during an eight-year forecast period 2016-2024, ... 2024. ...
Breaking Medicine Technology: